Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA OTC drugs-of-abuse testing interim policy allows kits on market without preclearance.

This article was originally published in The Tan Sheet

Executive Summary

FDA OTC DRUG TESTING INTERIM POLICY ALLOWS HOME DRUG TESTS for drugs of abuse to go on the market without premarket review. The one-page interim agency policy, issued Oct. 3, spells out FDA's plan to soften its regulatory stance on home-use drug tests while it develops a final agency policy defining what, if any, premarket requirements should be imposed on the tests. Prior to the interim policy, OTC drugs-of-abuse tests were deemed Class III devices, subject to premarket approval application requirements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts